Advancing Lymphoma Care: China’s CAR-T Innovation Shines
On the map of international medical tourism, China is becoming the preferred destination for more and more overseas patients with its advanced medical technology and cost-effective services.
In September 2024, Mr. Dell, a lymphoma patient from New Zealand, received a personalized CAR-T treatment plan provided by the domestic medical institution Yaoying Medical. He has achieved significant therapeutic effects. A review evaluation showed that the disease was completely in remission. This successful treatment This case once again proves China’s international competitiveness in the field of CAR-T treatment.
CAR-T therapy targeting CD19 demonstrates three major advantages
In July 2023, Mr. Dale was diagnosed with stage 4B lymphoma. After receiving third-line chemotherapy in New Zealand to no avail, he decided to go to Shanghai to receive a new CAR-T treatment plan, and chose Zhou Lili, director of the Department of Hematology at Shanghai Yaoying Hospital, as his attending physician.
According to the hospital’s diagnosis, Mr. Dell’s tumor had grown to 20cm and was compressing his organs. After realizing the difficulty and risk of treatment, the medical team chose CD19-targeted CAR-T therapy, also known as AKI. Lunsai injection. During Mr. Dell’s treatment, the hospital also implemented multidisciplinary consultation cooperation, including comprehensive assessment and close monitoring by the medical team, ensuring comprehensive assessment from pre-admission to strict monitoring after reinfusion.
In September 2024, Mr. Dell received a personalized bridging plan customized for him at Sunlight Medical and underwent CAR-T reinfusion therapy. During the treatment, Mr. Dale experienced no other uncontrollable risks, and reexamination showed that the disease was in complete remission.
Mr. Dell’s case has become a vivid reflection of the maturity of China’s CAR-T treatment technology. Zhou Lili said: “The bridging plan we specially formulated for Mr. Dell combines immunity, targeting, and radiotherapy to ensure that the tumor load is reduced as much as possible before the official CAR-T cell infusion is carried out, and the adverse effects after CAR-T treatment are reduced. Response and recurrence risk. “The implementation of this personalized treatment plan reflects China’s independent research and development capabilities in the field of CAR-T treatment and its service level that is in line with international standards.
The difficulty of treating lymphoma is often related to the patient’s age and overall health. These factors may lead to poor treatment efficacy or adverse reactions, thereby affecting the prognosis. Taking into account the particularity of Mr. Dell’s own symptoms, Sunlight Medical finally chose to perform CAR-T therapy on him based on the advantages of this new treatment method.
Zhou Lili believes that CAR-T therapy has obvious advantages over traditional chemotherapy in terms of cure rate, speed of action and side effects. In terms of cure rate, according to clinical trial data, CAR-T therapy can bring 60-90% of leukemia and lymphoma patients into remission; at the same time, CAR-T therapy can alleviate patients’ symptoms in a short time compared to traditional chemotherapy. , and quickly eliminate cancer cells; finally, CAR-T therapy has fewer side effects, and most side effects will gradually disappear after the treatment ends. This is because CAR-T therapy is highly targeted and can accurately identify and attack cancer cells without causing damage to normal cells.
China is one of the first countries to launch CAR-T therapy. Due to the large population base, large number of cases, and complex situations, domestic pharmaceutical companies have accumulated rich experience in diagnosis and treatment, which also gives domestic medical institutions significant advantages in the field of CAR-T treatment.
It is reported that Akilenza Injection is recognized by drug regulatory agencies in many countries and regions around the world and is used to treat specific lymphoma patients. In China, the Akilenza injection used by Mr. Dell this time is also the first CAR-T cell therapy product approved for marketing in China, which means that in China, patients can enjoy internationally recognized CAR-T. product. At present, domestic medical institutions have the product and technical reserves to provide patients with more mature treatment options.
Shanghai’s international medical services are booming
In addition to being in line with international standards in treatment methods, the current treatment costs provided by domestic medical institutions are also more acceptable to patients. According to reports, compared with the United States, the cost of CAR-T treatment in China is only one-fifth of that. Its medical capabilities and service quality are on par with international standards. This means patients can receive high-quality medical services at a lower cost, which is a huge attraction for international patients looking for cost-effective medical services.
Mr. Dell said: “When I decided to receive CAR-T treatment, the cost of treatment was indeed an important consideration. I also compared the cost of CAR-T treatment in different countries. According to the information I learned, China’s CAR- The cost of T treatment is the least burdensome to me and the most attractive.”
Looking to the future, Zhou Lili said that CAR-T therapy hopes to improve the therapeutic effect and inhibit tumor drug resistance by developing multi-target CAR-T treatment methods, while developing universal CAR-T technology and optimizing the preparation process. and automation, which can both reduce costs and make treatments more accessible.
A series of favorable policies have made cross-border medical tourism increasingly convenient in China. Mr. Dell introduced his feelings during his treatment in China: “Cultural differences are inevitable when you come to China. Yaoying Medical provides me with this aspect.” I received a lot of support. One is language. The hospital has a professional translation team that can help me quickly overcome language barriers and better communicate with medical staff. In terms of life, the hospital also gave me a lot of care and help, especially in terms of diet. Taking into account my eating habits, they provided me with special nutritious meals. ”
Shi Haoying, founder and CEO of Yaoying Medical, said: “We are committed to providing international patients with a full range of services, including not only high-quality medical services, but also the experience of Chinese culture. We realize that many overseas patients come to China not only to People who are seeking medical services are also interested in Chinese culture. Therefore, we have designed a series of services that allow patients to experience Chinese culture and history while enjoying medical services.”
With the continuous advancement of China’s medical technology and the deepening of international cooperation, more and more overseas patients choose to come to China for medical treatment. The successful case of Yaoying Medical not only demonstrates China’s technical strength in the field of CAR-T treatment, but also provides new options for the international medical tourism market. With the continuous development of medical tourism in China, industry professionals believe that more patients will choose to come to China for medical treatment in the future and choose high-quality, cost-effective medical services.
Advancing Lymphoma Care: China’s CAR-T Innovation Shines
On the map of international medical tourism, China is becoming the preferred destination for more and more overseas patients with its advanced medical technology and cost-effective services.
In September 2024, Mr. Dell, a lymphoma patient from New Zealand, received a personalized CAR-T treatment plan provided by the domestic medical institution Yaoying Medical. He has achieved significant therapeutic effects. A review evaluation showed that the disease was completely in remission. This successful treatment This case once again proves China’s international competitiveness in the field of CAR-T treatment.
CAR-T therapy targeting CD19 demonstrates three major advantages
In July 2023, Mr. Dale was diagnosed with stage 4B lymphoma. After receiving third-line chemotherapy in New Zealand to no avail, he decided to go to Shanghai to receive a new CAR-T treatment plan, and chose Zhou Lili, director of the Department of Hematology at Shanghai Yaoying Hospital, as his attending physician.
According to the hospital’s diagnosis, Mr. Dell’s tumor had grown to 20cm and was compressing his organs. After realizing the difficulty and risk of treatment, the medical team chose CD19-targeted CAR-T therapy, also known as AKI. Lunsai injection. During Mr. Dell’s treatment, the hospital also implemented multidisciplinary consultation cooperation, including comprehensive assessment and close monitoring by the medical team, ensuring comprehensive assessment from pre-admission to strict monitoring after reinfusion.
In September 2024, Mr. Dell received a personalized bridging plan customized for him at Sunlight Medical and underwent CAR-T reinfusion therapy. During the treatment, Mr. Dale experienced no other uncontrollable risks, and reexamination showed that the disease was in complete remission.
Mr. Dell’s case has become a vivid reflection of the maturity of China’s CAR-T treatment technology. Zhou Lili said: “The bridging plan we specially formulated for Mr. Dell combines immunity, targeting, and radiotherapy to ensure that the tumor load is reduced as much as possible before the official CAR-T cell infusion is carried out, and the adverse effects after CAR-T treatment are reduced. Response and recurrence risk. “The implementation of this personalized treatment plan reflects China’s independent research and development capabilities in the field of CAR-T treatment and its service level that is in line with international standards.
The difficulty of treating lymphoma is often related to the patient’s age and overall health. These factors may lead to poor treatment efficacy or adverse reactions, thereby affecting the prognosis. Taking into account the particularity of Mr. Dell’s own symptoms, Sunlight Medical finally chose to perform CAR-T therapy on him based on the advantages of this new treatment method.
Zhou Lili believes that CAR-T therapy has obvious advantages over traditional chemotherapy in terms of cure rate, speed of action and side effects. In terms of cure rate, according to clinical trial data, CAR-T therapy can bring 60-90% of leukemia and lymphoma patients into remission; at the same time, CAR-T therapy can alleviate patients’ symptoms in a short time compared to traditional chemotherapy. , and quickly eliminate cancer cells; finally, CAR-T therapy has fewer side effects, and most side effects will gradually disappear after the treatment ends. This is because CAR-T therapy is highly targeted and can accurately identify and attack cancer cells without causing damage to normal cells.
China is one of the first countries to launch CAR-T therapy. Due to the large population base, large number of cases, and complex situations, domestic pharmaceutical companies have accumulated rich experience in diagnosis and treatment, which also gives domestic medical institutions significant advantages in the field of CAR-T treatment.
It is reported that Akilenza Injection is recognized by drug regulatory agencies in many countries and regions around the world and is used to treat specific lymphoma patients. In China, the Akilenza injection used by Mr. Dell this time is also the first CAR-T cell therapy product approved for marketing in China, which means that in China, patients can enjoy internationally recognized CAR-T. product. At present, domestic medical institutions have the product and technical reserves to provide patients with more mature treatment options.
Shanghai’s international medical services are booming
In addition to being in line with international standards in treatment methods, the current treatment costs provided by domestic medical institutions are also more acceptable to patients. According to reports, compared with the United States, the cost of CAR-T treatment in China is only one-fifth of that. Its medical capabilities and service quality are on par with international standards. This means patients can receive high-quality medical services at a lower cost, which is a huge attraction for international patients looking for cost-effective medical services.
Mr. Dell said: “When I decided to receive CAR-T treatment, the cost of treatment was indeed an important consideration. I also compared the cost of CAR-T treatment in different countries. According to the information I learned, China’s CAR- The cost of T treatment is the least burdensome to me and the most attractive.”
Looking to the future, Zhou Lili said that CAR-T therapy hopes to improve the therapeutic effect and inhibit tumor drug resistance by developing multi-target CAR-T treatment methods, while developing universal CAR-T technology and optimizing the preparation process. and automation, which can both reduce costs and make treatments more accessible.
A series of favorable policies have made cross-border medical tourism increasingly convenient in China. Mr. Dell introduced his feelings during his treatment in China: “Cultural differences are inevitable when you come to China. Yaoying Medical provides me with this aspect.” I received a lot of support. One is language. The hospital has a professional translation team that can help me quickly overcome language barriers and better communicate with medical staff. In terms of life, the hospital also gave me a lot of care and help, especially in terms of diet. Taking into account my eating habits, they provided me with special nutritious meals. ”
Shi Haoying, founder and CEO of Yaoying Medical, said: “We are committed to providing international patients with a full range of services, including not only high-quality medical services, but also the experience of Chinese culture. We realize that many overseas patients come to China not only to People who are seeking medical services are also interested in Chinese culture. Therefore, we have designed a series of services that allow patients to experience Chinese culture and history while enjoying medical services.”
With the continuous advancement of China’s medical technology and the deepening of international cooperation, more and more overseas patients choose to come to China for medical treatment. The successful case of Yaoying Medical not only demonstrates China’s technical strength in the field of CAR-T treatment, but also provides new options for the international medical tourism market. With the continuous development of medical tourism in China, industry professionals believe that more patients will choose to come to China for medical treatment in the future and choose high-quality, cost-effective medical services.